Company: IPSC
Filing Date: 2025-07-10
Form Type: S-3
Source: 0001104659-25-067022
Chunk: 8

Company: Century Therapeutics, Inc.
Filing Date: 2025-07-10
Form: S-3
Chunk 8
---
 the development of our current and future product candidates;

•

the early clinical nature of our business and our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials;

•

our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;

•

the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;

•

our dependence on the success of our lead product candidate, CNTY-101, and our ability to progress CNTY-101 through clinical development;

•

the novelty of our approach to immuno-oncology and autoimmune and inflammatory treatments, utilizing iPSC-derived natural killer cells, or iNK cells, and iPSC-derived T cells, or iT cells, and the challenges we will face due to the novel nature of such technology;

•

the success of competing therapies that are or may become available;

•

our reliance on the maintenance of our collaborative relationship with FUJIFILM Cellular Dynamics Inc., or FCDI, for access to key differentiation and reprogramming technology for the manufacturing and development of our product candidates;

•

the initiation, progress, success, cost, and timing of our development activities, preclinical studies and clinical trials;

•

the timing of future investigational new drug, or IND, applications and the likelihood of, and our ability to obtain and maintain, regulatory clearance of IND applications for our product candidates;

•

the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;

•

the performance of third parties in connection with the development of our product candidates, including third parties conducting our current and future clinical trials as well as third-party suppliers and manufacturers;

•

our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;

•

the public opinion and scrutiny of cell-based immuno-oncology and autoimmune and inflammatory therapies and its potential impact on public perception of our company and product candidates;

•

our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;

•

the size and growth of the potential markets for our product candidates and our ability to serve those markets;

•

regulatory developments and approval pathways in the United States and foreign countries for our product candidates;

•

the potential scope and value of our intellectual property and proprietary rights;

•

our ability, and the ability of our licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability